Dual targeted therapy with pyrotinib and trastuzumab for HER2‐positive advanced colorectal cancer: A phase 2 trial

This trial was initiated to evaluate the efficacy and safety of pyrotinib in combination with trastuzumab in patients with human epidermal growth factor receptor 2 (HER2)‐positive recurrent/metastatic colorectal cancer (CRC). In this single‐arm, open‐label, multicenter, phase 2 trial patients with H...

Descripción completa

Detalles Bibliográficos
Autores principales: Fu, Xianhua, Ying, Jieer, Yang, Liu, Fang, Weijia, Han, Weidong, Hu, Hanguang, Zhang, Suzhan, Yuan, Ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9986078/
https://www.ncbi.nlm.nih.gov/pubmed/36382603
http://dx.doi.org/10.1111/cas.15660

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9986078/
https://www.ncbi.nlm.nih.gov/pubmed/36382603
http://dx.doi.org/10.1111/cas.15660

Ejemplares similares